Advertisement

Topics

POXEL S.A. Company Profile

18:54 EDT 21st October 2018 | BioPortfolio

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., Europe and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences is responsible for Imeglimin’s development and commercialization in countries outside of Poxel’s partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is advancing into a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. DRX-065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC), is in Phase 1 and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs, including deuterated drug candidates for metabolic, specialty and rare diseases. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com)


News Articles [25 Associated News Articles listed on BioPortfolio]

Poxel licenses NASH project from DeuteRx

DeuteRx LLC granted Poxel SA exclusive global rights to DRX065, a Phase I candidate that Poxel intends to develop for nonalcoholic steatohepatitis (NASH).

Poxel completes enrolment in TIMES 1 trial

Poxel has completed patient enrolment for the TIMES 1 trial in Japan to investigate the use of Imeglimin for the...Read More... The post Poxel completes enrolment in TIMES 1 trial appeared first on Dr...

Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan

French biopharmaceutical firm Poxel has concluded patient enrolment in the Phase III TIMES 2 clinical trial of its drug candidate...Read More... The post Poxel closes enrolment in TIMES 2 trial of Ime...

Poxel reports positive results from PXL770 phase 1b MAD trial and drug─drug interaction study

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non─alcoholic steatohepatitis (NASH), has announced f...

Poxel Adds To NASH Pipeline With Novel Single-Isomer Pioglitazone

Some ground-breaking chemistry has been used to produce a single isomer of pioglitazone, which has been acquired by France's Poxel...   

Deals this week: Biohaven Therapeutics, POXEL, Ossianix

Biohaven Therapeutics has signed a licensing agreement with AstraZeneca for a new drug candidate, AZD3241, targeting a rare neurodegenerative disease....Read More... The post Deals this week: Biohaven...

Poxel Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference

POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic diseases, including type 2 diabe...

Poxel Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference

POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Safety, Tolerability and PK of PXL770 in Healthy Male Subjects

PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK) being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM). In Part A of ...

Companies [2 Associated Companies listed on BioPortfolio]

Poxel SAS

Poxel is a new RIPCO that aims to advance promising assets for cardio-metabolic diseases from Research to Phase 2 Clinical Proof of Concept, before out licensing projects to pharmaceutical compani...

POXEL S.A.

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alco...

More Information about "POXEL S.A." on BioPortfolio

We have published hundreds of POXEL S.A. news stories on BioPortfolio along with dozens of POXEL S.A. Clinical Trials and PubMed Articles about POXEL S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of POXEL S.A. Companies in our database. You can also find out about relevant POXEL S.A. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record